Journal
NATURE REVIEWS NEUROLOGY
Volume 9, Issue 8, Pages 455-461Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrneurol.2013.118
Keywords
-
Categories
Funding
- Austrian Science Fund (FWF) [W1206, I916]
- Jubilaeumsfonds of the Austrian National Bank [14158]
- Austrian Science Fund (FWF) [I 916] Funding Source: researchfish
- Austrian Science Fund (FWF) [I916] Funding Source: Austrian Science Fund (FWF)
Ask authors/readers for more resources
Myelin oligodendrocyte glycoprotein (MOG) has been identified as a target of demyelinating autoantibodies in animal models of inflammatory demyelinating diseases of the CNS, such as multiple sclerosis (MS). Numerous studies have aimed to establish a role for MOG antibodies in patients with MS, although the results have been controversial. Cell-based immunoassays using MOG expressed in mammalian cells have demonstrated the presence of high-titre MOG antibodies in paediatric patients with acute disseminated encephalomyelitis, MS, aquaporin-4-seronegative neuromyelitis optica, or isolated optic neuritis or transverse myelitis, but only rarely in adults with these disorders. These studies indicate that MOG antibodies could be associated with a broad spectrum of acquired human CNS demyelinating diseases. This Review article discusses the current literature on MOG antibodies, their potential clinical relevance, and their role in the pathogenesis of MOG antibody-associated demyelinating disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available